Examples of 'benefit-risk balance' in a sentence
Meaning of "benefit-risk balance"
benefit-risk balance ~ weighing the advantages and disadvantages of a particular action or decision
How to use "benefit-risk balance" in a sentence
Basic
Advanced
benefit-risk balance
Overall conclusion and benefit-risk balance.
The benefit-risk balance is largely in favor of sport.
Evaluation of the overall benefit-risk balance.
The benefit-risk balance of the veterinary medicinal product is no longer positive ;.
Scientific evaluation of the benefit-risk balance.
Affecting the benefit-risk balance of the vaccine.
Evaluation and conclusions on the benefit-risk balance.
An improvement of the benefit-risk balance of the veterinary medicinal product.
Evaluation and conclusion on the benefit-risk balance.
The benefit-risk balance for the agreed indication is considered favourable.
It allows continued monitoring of the benefit-risk balance of the medicinal product.
The benefit-risk balance of the applied medicinal product is considered positive.
In the absence of established efficacy, a positive benefit-risk balance has not been established.
The benefit-risk balance of concomitant treatment with pirfenidone has not been established.
This examination should include a re-assessment of the benefit-risk balance in the individual patient.
See also
A positive benefit-risk balance has been established in elective surgery and trauma patients.
This may not necessarily preclude an overall positive benefit-risk balance at the time of authorisation.
The benefit-risk balance for these medicinal products remains therefore positive.
The information can not be used in isolation to decide upon the benefit-risk balance of a medicine.
Draw up a conclusion on the benefit-risk balance for the veterinary medicinal product.
Benefit-risk balance of the vaccine.
The bioequivalence is therefore established and the benefit-risk balance for these products remains positive.
The benefit-risk balance is therefore negative and the indication should be deleted.
The Committee considered that the benefit-risk balance of dihydroergocristine containing products,.
The benefit-risk balance for fusafungine-containing medicines is therefore negative for all currently authorised uses.
EC was therefore initiated, to review the benefit-risk balance of testosterone containing medicinal products.
The benefit-risk balance may be found in the scientific discussion of this EPAR.
The Committee considered that the benefit-risk balance of nicergoline containing products,.
The benefit-risk balance can be found in the scientific discussion module of this EPAR.
Results from clinical studies show a negative benefit-risk balance in tumours with RAS mutations.
The benefit-risk balance may be found in Pr.
The Committee maintained its opinion that the benefit-risk balance of dihydroergotoxine containing products,.
The benefit-risk balance of Corlentor / Procoralan remains positive for its authorised indications.
Therefore the Committee considered that the benefit-risk balance of metoclopramide in these indications is negative.
The benefit-risk balance may be found in module 6 of this.
Therefore the CHMP was of the opinion that the benefit-risk balance of methysergide containing products,.
The benefit-risk balance of the medicine is not favourable ;.
None of the new ADR reports shift the benefit-risk balance of the childhood vaccines.
The benefit-risk balance of the veterinary medicinal product is negative ;.
Conclusion on the benefit-risk balance.
The benefit-risk balance of the veterinary medicinal product is unfavourable ;.
Conclusions on the benefit-risk balance.
The benefit-risk balance remains positive only for the following uses,.
Use of letermovir prophylaxis for greater than 100 days requires a careful assessment of the benefit-risk balance.
In view of the above, the benefit-risk balance for this indication is considered negative.
The benefit-risk balance can be found in module 6 of this EPAR.
The CHMP considered, as a consequence, that the benefit-risk balance of Syner-Kinase is favourable.
Therefore, the benefit-risk balance for Numeta G13%E as currently formulated is considered as not favourable.
The Committee, as a consequence, considers that the benefit-risk balance of Diclofenac is not favourable.
Thus the overall benefit-risk balance for such product formulations is considered negative.
You'll also be interested in:
Examples of using Benefit-risk
Show more
Benefit-risk analysis and risk management
Overall conclusion and benefit-risk balance
Integrated benefit-risk analysis for authorised indications
Examples of using Balance
Show more
Adjusting the balance effects all sources
Balance the blade following the instructions
Adjusting the white balance manually recommended
